Retrospective Reviews and Prospective Case Studies
Wound chronicity is when any type of wound “stalls” in the proliferative phase. Healthcare professionals worldwide are always looking for the latest and greatest "fix-all" wound dressing. Both clinicians and patients share the challenges faced in battling this common phenomenon. Patients try to bear the substantial clinical, personal, and economic burdens of having a non-healing wound. Faster healing times are essential in decreasing the chances of biofilm formation and infection.
Human Biosciences advanced wound care product options provide clinicians with more practical choices in their "wound care toolbox" versus traditional wound care dressings. This technology offers collagen in its purest form, optimizing a scaffolding system for new cells, debrided devitalized tissue, encourage the formation of new blood vessels, and support tightening wound edges.
Human BioSciences has compiled thousands of field studies on patients with chronic wounds and various etiologies. This data repeatedly validates the value of Medifil® II and SkinTemp® II advanced wound care products. Human BioSciences quality product formulations (particles, sheets, gel) provide an optimal moist wound healing environment while moving non-healing wounds through the healing trajectory.
Results of Retrospective Reviews Utilizing Medifil® II and SkinTemp® II
| Author | Lasday | Baxter | Kollenburg | Carter | Erickson |
|---|---|---|---|---|---|
|
Status |
Hospital |
Wound Center |
Multiple |
PHS* |
Home Care |
|
No. of Patients |
700 |
700 |
1,000 |
100 |
100 |
|
Wound Type |
Chronic |
Chronic |
Multiple |
Multiple |
E.B. |
|
Results |
Significantly faster healing rate |
Significantly faster healing rate |
Greater than 95% wound closure rate |
Cost effective wound closure |
Quality of life enhancement |
Results of Prospective Studies Utilizing Medifil® II and SkinTemp® II
|
Author |
Lasday |
Lefell |
Griswold |
Griswold2 |
Kollenburg |
|---|---|---|---|---|---|
|
Status |
Abstract |
Published |
Published |
Abstract |
Abstract |
|
No. of Patients |
40 |
15 |
8 |
40 |
20 |
|
Wound Type |
Chronic |
Post-Mohs |
Donor Site |
Graft |
Surgical |
|
Accelerated Healing Rate |
40% |
50% |
30% |
40% |
30-40% |
The wound care industry's emphasis on outcome-based healing requires advanced solutions. Now, HBS's KollagenTM technology gives clinicians an effective alternative to traditional wound management dressings.
Clinical Research: Comparing the Healing Effectiveness of Wound Care Products
Studies of different wound types compare collagen products to traditional dressings
